期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

有应用华法林指征且植入冠状动脉支架患者抗栓策略的选择 被引量：1

下载PDF
导出
摘要 目前对于既有应用华法林指征且又植入冠状动脉支架者抗栓策略的选择尚缺乏大规模的循证医学证据。故现阶段,对于此类患者需慎重权衡出血和血栓的风险,选择个体化的抗栓策略。血栓栓塞低危或仅存一个中危因素的患者,可选用阿司匹林加氯吡格雷二联抗栓治疗,而对于存在1个以上中危因素或1个高危因素的患者则可能需要在严密监测国际标准化比率的基础上选择三联抗栓策略,而对于高龄患者,阿司匹林加氯吡格雷二联抗栓策略可能更为合适。
作者 孙育民 王骏 刘旭
机构地区 上海市静安区中心医院心内科 上海交通大学附属胸科医院心内科
出处 《中国心脏起搏与心电生理杂志》 北大核心 2009年第4期357-359,共3页 Chinese Journal of Cardiac Pacing and Electrophysiology
关键词 心血管病学 冠心病 综述 支架 华法林 阿司匹林 氯吡格雷
分类号 R541.4 [医药卫生—心血管疾病] R973.2 [医药卫生—药品]
  • 相关文献

参考文献24

  • 1Popma JJ, Berger P, Ohman EM, et al. Antithrombotic therapy during percutaneous coronary intervention. The seventh ACCP conference on antithrombotic and thrombolytic therapy [J]. Chest, 2004,126:576S.
  • 2Smith Jr SC, Feldman TE, Hirshfeld Jr JW, et al. ACC/AHA/ SCAI2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines ( ACC/AHA/SCAI writing committee to update the 2001 guidelines for percutaneous coronary intervention) [ J]. Circulation,2006,113 : 156.
  • 3Rubboli A, Colletta M, Sangiorgio P, et al. Antithrombotic treatment after coronary artery stenting in patients on chronic oral anticoagulation: an international survey of current clinical practice [ J ].ltal Heart J ,2004,5:851.
  • 4Rubboli A, Colletta M, Herzfeld J, et al. Peri-procedural and mediumterm antithrombotic strategies in patients with an indication for longterm anticoagulation undergoing coronary angiography and intervention [ J ]. Coron Artery Dis,2007,18 : 193.
  • 5Porter A, Konstantino Y, lakobishvili Z, et al. Short-term triple therapy with aspirin, warfarin, and a thienopyridine among patients undergoing percutaneous coronary intervention[ J ]. Catheter Cardiovasc lnterv ,2006,68:56.
  • 6Lip GYH, Karpha M. Anticoagulant and antiplatelet therapy use in patients with atrial fibrillation undergoing percutaneous coronary intervention: the need for consensus and a management guideline[ J ]. Chest, 2006,130:1 823.
  • 7Orford JL, Fasseas P, Melby S, et al. Safety and efficacy of aspirin, clopidogrel,and warfarin after coronary stent placement in pa- tients with an indication for anticoagulation [ J ]. Am Heart J,2004, 147 : 463.
  • 8Mattichak SJ, Reed PS, Gallagher M J, et al. Evaluation of safety of warfarin in combination with antiplatelet therapy for patients treated with coronary stents for acute myocardial infarction [ J ]. J Interv Cardio1,2005,18 : 163.
  • 9DeEugenio D, Kolman L, DeCaro M, et al. Risk of major bleeding with concomitant dual antiplatelet therapy after percutaneous coronary intervention in patients receiving long-term warfarin therapy[J]. Pharmacotherapy,2007 ,27 :691.
  • 10Khurram Z, Chou E, Minutello R, et al. Combination therapy with aspirin, clopidogrel and warfarin following coronary stenting is associated with a significant risk of bleeding[J]. J Invasive Cardiol, 2006,18 : 162.

同被引文献20

  • 1Furuta T, Iwaki T, Umemura K.Pantoprazole breath test as a predictor of the anti-platelet function of clopidogrel[J]. Eur J Clin Pharmacol, 2010,66 ( 5 ) : 457.
  • 2Fontana P, Bonvini RF, Roffi M, et al.Evaluating the biological efficacy of clopidogrel: genotype or phenotype? [J]. Rev MedSuisse, 2010,6(235) :302.
  • 3Giusti B, Gori AM, Marcucci R, et al. Cytochrome P4a02C 19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients[J]. Pharmacogenet Genomics, 2007,17(12) : 1 057.
  • 4Sibbing D, Koch W, Gebhard D, et al.Cytochrome 2C 19* 17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement[J]. Circulation, 2010, 121 (4) : 512.
  • 5Sorich M J, Vitry A, Ward MB, et al. Prasugrel versus clopidogrel for Cytochrome P4502C19 genotyped subgroups: integration of the TRITON-TIMI 38 trial data[J]. J Thromb Haemost,2010,8(8) :1 678.
  • 6Sibbing D, Gebhard D, Koch W, et al.Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy[J]. J Thromb Haemost,2010,8(8) : 1 685.
  • 7Allen C, Dunn SP, Macaulay TE, et al.Clopidogrel-proton pump inhibitor interaction: a primer for clinicians[J].Cardiovasc Hematol DisordDrug Targets, 2010,10( 1 ) : 66.
  • 8Laine L, Hennekens C.Proton pump inhibitor and clopidogrel interaction: fact or fiction[J].Am J Gastroenterol, 2010,105(1): 34.
  • 9Kenngott S, Olze R, Kollmer M, et al.Clopidogrel and proton pump inhibitor (PPI) interaction: separate intake and a non-omeprazole PPI the solution[J]. Eur J Med Res, 2010,15(5): 220.
  • 10Small DS, Farid NA, Li YG, et al. Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel[J]. Curt Med Res Opin, 2008, 24 (8) : 2 251.

引证文献1

二级引证文献11

中国心脏起搏与心电生理杂志
2009年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部